Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: A prodrug strategy as an alternative approach
✍ Scribed by Paul K. Kiptoo; Kalpana S. Paudel; Dana C. Hammell; Raghotham Reddy Pinninti; Jianhong Chen; Peter A. Crooks; Audra L. Stinchcomb
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 171 KB
- Volume
- 98
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
✦ Synopsis
This investigation includes an evaluation of the percutaneous absorption of bupropion (BUP) and hydroxybupropion (BUPOH) in vitro and in vivo. In addition, a carbamate prodrug of BUPOH (But-BUPOH) was evaluated in vitro. In vitro diffusion studies were conducted in a flow-through diffusion cell system. The in vitro mean steady-state flux of BUP was significantly higher ( p < 0.001) compared to BUPOH (320 AE 16 nmol cm À2 h À1 vs. 27 AE 4 nmol cm À2 h À1 ). Additionally, a good correlation existed between in vitro and in vivo results. Mean steady-state plasma concentrations of 442 AE 32 ng/mL and125 AE 18 ng/mL were maintained over 48 h after topical application of BUP and BUPOH in hairless guinea pigs in vivo, respectively. Although BUP traversed human skin at rates sufficient to achieve required plasma levels, it is chemically unstable and hygroscopic, and unsuitable for transdermal formulation. On the other hand, BUPOH is stable but its transport across skin is much slower. Alternatively, the prodrug But-BUPOH was found to be stable, and also provided a 2.7-fold increase in the transdermal flux of BUPOH across human skin in vitro. Thus, But-BUPOH provides a viable option for the transdermal delivery of BUPOH. ß 2008